Abstract
Denosumab is a fully human monoclonal antibody, the first RANKL inhibitor to be approved by the FDA, now available for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma and giant cell tumour of bone. Precursors of osteoclasts, called pre-osteoclasts, express the surface receptor RANK (receptor activator of nuclear factor kappa B), a member of the tumour necrosis factor receptor (TNFR) family. RANK is activated by the ligand RANKL, which are cell surface molecules on osteoblasts. Activation of RANK by RANKL promotes the differentiation of pre-osteoclasts to active osteoclasts. Denosumab inhibits this maturation of osteoclasts by binding to and inhibiting RANKL. This reaction mimics the natural action of osteoprotegerin (OPG) and protects bone from resorption.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAuthor information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Bartl, R., Bartl, C. (2017). Other Drugs in Osteoporosis. In: Bone Disorders . Springer, Cham. https://doi.org/10.1007/978-3-319-29182-6_30
Download citation
DOI: https://doi.org/10.1007/978-3-319-29182-6_30
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-29180-2
Online ISBN: 978-3-319-29182-6
eBook Packages: MedicineMedicine (R0)